The Zhitong Finance App learned that BOC International released a research report stating that it maintains the “buy” rating of Kingsley Biotech (01548), with a target price of HK$27.75. The bank expects that the approval of Carvykti's new indications will significantly reduce the OOS of the product and gradually release new production capacity. Sales are expected to rise rapidly every quarter starting in the second half of the year. As the investment and financing environment continues to recover, the CDMO (Booming Bio) sector's performance has exceeded expectations. For the life sciences services sector and Bestmaster, the company is leading to strong annual revenue growth of 15%-20% and 20%-30% (@CER, i.e. comparative effectiveness study).